Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database.
Misa NaganumaYumi MotookaSayaka SasaokaHaruna HatahiraShiori HasegawaAkiho FukudaSatoshi NakaoKazuyo ShimadaKoseki HiradeTakayuki MoriTomoaki YoshimuraTakeshi KatoMitsuhiro NakamuraPublished in: SAGE open medicine (2018)
Our findings suggest a potential risk of renal impairment during cisplatin use in real-world setting. The present findings demonstrate that the incidence of renal impairment following cisplatin use should be closely monitored when patients are hypertensive or diabetic, or when they are co-administered furosemide, loxoprofen, or pemetrexed. In addition, healthcare professionals should closely assess a patient's background prior to treatment.
Keyphrases
- adverse drug
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- blood pressure
- type diabetes
- chronic kidney disease
- risk factors
- emergency department
- electronic health record
- prognostic factors
- peritoneal dialysis
- case report
- drug induced
- advanced non small cell lung cancer
- human health
- risk assessment
- replacement therapy
- climate change